Interview: KaNDy Menopause Therapy Hits Sweet Spot
NT-814 Set For Phase III Trials
Executive Summary
Prospective partners will be impressed by data which shows that the UK company's once-daily oral treatment reduces hot flashes and night sweats and has also shown very rapid improvements in mood and sleep.
You may also be interested in...
GSK Spin-Off Launches KaNDy To Tackle Key Symptoms Of Menopause
NeRRe Therapeutics has set up a new entity around a drug which it believes could be an effective alternative to hormone replacement therapy for hot flashes that may rapidly reduce debilitating sleep disturbance.
AZ Closer To Second Enhertu OK After Gastric Cancer Success
The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.
J&J's Stelara Gets Europe OK For Pediatric Psoriasis
The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.
Need a specific report? 1000+ reports available
Buy Reports